Confidence in Concept 2012 - Edinburgh

Lead Research Organisation: University of Edinburgh

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description BBSRC Alert 17 (Mass spec)
Amount £722,150 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 05/2018 
End 04/2019
 
Description BioQuarter Innovation Competition Winner - Development of a Hepatic Vascular Cathetar CiC1
Amount £15,000 (GBP)
Organisation University of Edinburgh 
Sector Academic/University
Country United Kingdom
Start 05/2014 
End 04/2015
 
Description CATACURE ICT Policy Support Programme
Amount € 2,700,000 (EUR)
Funding ID 6210885 
Organisation European Commission 
Department Competitiveness and Innovation Framework Programme (CIP)
Sector Public
Country European Union (EU)
Start  
 
Description Chief Scientist Office - Catalytic Grant (Mass Spec)
Amount £34,000 (GBP)
Organisation Chief Scientist Office 
Sector Public
Country United Kingdom
Start 11/2018 
End 04/2019
 
Description CiC 20012 (steriods)
Amount £14,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 03/2023
 
Description CiC 2012 ((fibre optic)
Amount £108,000 (GBP)
Organisation Heriot-Watt University 
Sector Academic/University
Country United Kingdom
Start 10/2016 
End 10/2017
 
Description CiC 2012 (Steroids)
Amount £104,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 09/2017 
End 09/2021
 
Description CiC 2012 (fetal diagnostic)
Amount £49,000 (GBP)
Organisation Carnegie Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 09/2018
 
Description CiC 2012 (fetal diagnostic)
Amount £108,000 (GBP)
Organisation Medical Research Scotland 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 09/2019
 
Description CiC 2012 (fetal diagnostic)
Amount £250,000 (GBP)
Organisation Chief Scientist Office 
Sector Public
Country United Kingdom
Start 10/2016 
End 03/2019
 
Description CiC 2012 (fetal diagnostic)
Amount € 2,500 (EUR)
Organisation German Academic Exchange Service (DAAD) 
Sector Public
Country United States
Start 06/2017 
End 06/2020
 
Description CiC 2012 (fetal diagnostic)
Amount € 2,500 (EUR)
Organisation German Academic Exchange Service (DAAD) 
Sector Public
Country United States
Start 06/2017 
End 06/2020
 
Description CiC 2012 (hepatic vascular catheter)
Amount £40,000 (GBP)
Organisation NHS Scotland 
Sector Public
Country United Kingdom
Start 03/2016 
End 03/2017
 
Description CiC 2012 (micro BRT)
Amount £108,000 (GBP)
Organisation Medical Research Scotland 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 09/2024
 
Description CiC 2012 (personalised voices)
Amount £40,000 (GBP)
Organisation Digital Health Institute (DHI) 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2016 
End 04/2018
 
Description CiC A device for label free purification of viable cells for therapy
Amount £50,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description CiC TissueStik
Amount £370,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 12/2016 
End 09/2019
 
Description CiC personalised voices for patients with MND
Amount £127,000 (GBP)
Organisation Motor Neurone Disease Association (MND) 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description CiC2012 (Steriods)
Amount £2,000 (GBP)
Organisation British Mass Spectrometry Society 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2016 
End 03/2017
 
Description CiC2012 (Steroids) WT-ISSF2 funding
Amount £44,000 (GBP)
Funding ID X00000294 
Organisation Wellcome Trust 
Department Wellcome Trust Institutional Strategic Support Fund
Sector Charity/Non Profit
Country United Kingdom
Start 05/2016 
End 05/2026
 
Description Clinical Research Career Development Fellowship (mirPOC)
Amount £472,987 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Company contribution - Catanostics CiC1
Amount € 1,300,000 (EUR)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start  
 
Description EPSRC - FetaSAFE CiC 1
Amount £1,300,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 02/2018 
End 01/2022
 
Description GSK CASE PhD Studentship - Developing Mass Spec Imaging CiC1
Amount £120,000 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start  
 
Description Industry studentship Johnson Matthey (mircoBRT CIC1)
Amount £116,900 (GBP)
Organisation Johnson Matthey 
Sector Private
Country United Kingdom
Start 10/2018 
End 09/2022
 
Description Institutional Strategic Support Fund (micro-BRT)
Amount £30,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 07/2017
 
Description Institutional Translational Partnership Award (iTPA) Mass Spec project
Amount £20,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2018 
End 04/2019
 
Description Kidney Research UK (mirPOC)
Amount £124,482 (GBP)
Organisation Kidney Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2019
 
Description Kidney Research UK - Developing Mass Spec Imaging CiC1
Amount £63,000 (GBP)
Organisation Kidney Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2020
 
Description Michael Smith Foreign Study Supplement (Mass spec)
Amount $6,000 (CAD)
Organisation Michael Smith Foundation for Health Research 
Start 03/2018 
End 09/2018
 
Description Moray Trust - for label free purification project CIC1
Amount £5,000 (GBP)
Organisation Moray Council 
Sector Public
Country United Kingdom
Start 02/2017 
End 03/2018
 
Description Multiplicom funding (Fetasafe)
Amount £10,000 (GBP)
Organisation Multiplicom N.V. 
Sector Private
Country Belgium
Start  
 
Description Multiuser Equipment Grant (Steroids)
Amount £850,000 (GBP)
Organisation Wellcome Trust 
Department Wellcome Trust Bloomsbury Centre
Sector Academic/University
Country United Kingdom
Start 03/2016 
End 03/2017
 
Description NHS Research Scotland Career Fellow - Development of a Hepatic Vascular Cathetar CiC1
Amount £125,000 (GBP)
Organisation NHS Research Scotland 
Sector Public
Country United Kingdom
Start 04/2014 
End 03/2017
 
Description PhD based collaboration with Axis Shield - Mircro BRT - CiC 1
Amount £120,000 (GBP)
Organisation Axis-Shield 
Sector Private
Country United Kingdom
Start  
 
Description Rosetree Trust Interdisciplinary Prize - mirPOC CiC1
Amount £250,000 (GBP)
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2019
 
Description Scottish Enterprise High Growth Spin out - FetaSAFE CiC1
Amount £174,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 09/2017 
End 08/2018
 
Description Scottish Government Clinical Evaluation - Personlised voices for MND CiC 1
Amount £200,000 (GBP)
Organisation Government of Scotland 
Sector Public
Country United Kingdom
Start 04/2016 
End 03/2017
 
Description Travel Award - Mass Spec project
Amount £800 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2018 
End 09/2018
 
Description UKRMP funding - mirPOC - CiC1
Amount £60,000 (GBP)
Organisation UK Regenerative Medicine Platform 
Sector Academic/University
Country United Kingdom
Start 11/2014 
End 10/2015
 
Title CiC A device for label free purification of viable cells for therapy 
Description Viable and non-viable cells can also be separated by manipulating their movement in non-uniform electric fields (dielectrophoresis, DEP). This is because, when cells die, their size, plasma-membrane capacitance and ionic porosity change, resulting in changes in the electric field frequencies at which the dielectric properties of the cells exactly match those of the surrounding medium (the so-called DEP crossover frequency or Fxo). By using microelectrodes energised with AC voltages in a defined range of frequencies, distinct Fxos can be established for viable, as compared with non-viable, cells. For example, viable cells typically exhibit a dynamic distribution of DEP Fxos ranging from 50-250 kHz while non-viable cells progress from the upper value of this range beyond 400 kHz as apoptosis progresses1. Such differences in DEP responses can be used to sort cells with high efficiency. Indeed, different cell types of similar size (namely myoblasts and fibroblasts) can be efficiently sorted in this way (to 98% purity at sorting rates of around 2x105 cells per hour) because of differences in their plasma membrane capacitance2. Since differences in DEP responses between viable and non-viable cells are more substantial, we anticipate that increased flow rates can be used to sort viable from non-viable cells more rapidly and that, in combination with 1g sedimentation prior to DEP sorting, rates of viable-cell purification of 106-109 cells per hour can be achieved. 
Type Of Material Technology assay or reagent 
Year Produced 2014 
Provided To Others? Yes  
Impact Investigator has completed a stage 1 H2020 application which could be relevant feedback since, if successful it will extend what we learned about DEP during the CiC (and without the CiC we wouldn't have made the application!). I am leading the application on behalf of UEDIN and the consortium is called CRYOREV (16 partners, a mixture of academic and commercial institutions) and the call is Tools and technologies for advanced therapies PHC-16-2015. The project is entitled Automated revival and monitoring of cryopreserved cells for regenerative therapies, with a DEP cytometer being developed to be used on the monitoring side (one of the work packages). If successful it will provide funding of almost 6 million Euros Dielectrophoresis has the potential to be applied to all types of cell for assessment of viability - for example for pancreatic islet viability analysis. Determination of islet viability prior to transplantation is critical but current techniques are sub-optimal. Based on findings from this CiC project, funding was secured from the EPSRC to investigate translating this technology to pancreatic islet viability testing alongside use of a novel technique for pancreatic islet isolation. The EPSRC project is a collaboration between The Universities of Edinburgh, Newcastle and Heriot-Watt. We also secured a small equipment grant from the Moray Endowment fund to purchase specialised equipment for the latter part of the CiC project. 
 
Title CiC MicroBRT 
Description A reagent was developed that can stabilise and extract bacterial RNA from whole blood. A microfluidic device was developed that could process this whole blood in this reagent to prepare samples suitable for bacterial RNA analysis. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact This method is suitable for use in a determination of bacterial RNA in a point of care device that should be able to rapidly report on the early outcome of antibiotic therapy. 
 
Description Aquila Biomedical (Tissuestik) 
Organisation Aquila BioMedical
PI Contribution Tissuestik service was incorporated into Aquila BioMedical suite of services
Collaborator Contribution Aquila recognised the value of this service and incorporated into their business
Impact This service supports the company who have increased their turnover and staff numbers and the company was acquired by Concept Life Sciences in 2017.
Start Year 2014
 
Description Arrotek Medical Devices (Hepatic Vascular Catheter) 
Organisation Arrotek Medical Limited
PI Contribution Idea was presented to the company
Collaborator Contribution The project utilised cadaveric testing initially to confirm that the balloon design had potential applicability. Key strength was brought to the project by Arrotek, a balloon design, prototyping and manufacturing company based in Ireland. Arrotek were able to develop iterations rapidly and had a strong understanding of biomedical product development. Having developed a working example, preclinical studies were carried out at UMC Utrecht. This is a first class vascular interventional facility. Fully supported with dedicated theatre staff and interventional radiology, the functional characteristics of the catheter were assessed in vivo and recorded with digital stills, video and angiography.
Impact This product has not developed further due to licensing and patent issues - mainly lack of funding for patents at Univ of Edinburgh and lack of commercial interest from external sources to take this product to market.
Start Year 2013
 
Description Catanostics CiC 1 
Organisation Seafield and Cullen Medical Group
PI Contribution Data and IP
Collaborator Contribution Expertise, Commercial help
Impact Company are applying for a SMART Award in 2017. Outcome to be recorded.
Start Year 2013
 
Description CiC Catanostics 
Organisation Heriot-Watt University
Department Chemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution Catanostics EU & HWU has obtained support entitled 'CATACURE' The total project is €2.7M and has 5 partners across Europe; Sweden and Denmark (opthalmic hospitals), Denmark (optical filters), UK (Edinburgh Biosciences - cataract monitoring is becoming a major part of EBS business), Germany (instrument manufacture). These SMEs have themselves have committed €1.4M cash investment which took a lot of negotiation! Bal Dhillon will Chair the Steering group for this project, keeping a UoE hand in it. The project will deliver several prototype instruments that will provide the appropriate laser illumination for therapy for trials in the opthalmic hospitals and Asia. This ought to be a strong output for the CiC award.
Collaborator Contribution These SMEs have themselves have committed €1.4M cash
Impact Multi-disciplinary academic medical and industrial product development project.
Start Year 2013
 
Description CiC EPDD 002 CATANOSTICS 
Organisation Edinburgh Instruments Ltd
Country United Kingdom 
Sector Private 
PI Contribution we are building the device
Collaborator Contribution partner is providing very valuable hardware
Impact Project complete all miles met.
Start Year 2013
 
Description CiC EPDD 010 A portable integrated device for organ recovery from donors after circulatory death under normothermic conditions. 
Organisation University of Strathclyde
Department Department of Biomedical Engineering
Country United Kingdom 
Sector Academic/University 
PI Contribution we are providing the portable device
Collaborator Contribution Partners are providing the oxygenation system
Impact too early in CiC
Start Year 2013
 
Description CiC EPDD 011 mirPOC - detection of miRNAs indicating drug-induced liver injury at point-of-care. 
Organisation Mölnlycke Healthcare Ltd
Department Mölnlycke Health Care–Scotland (MHC-S)
Country United Kingdom 
Sector Academic/University 
PI Contribution We are bringing analyte to distinguish disease (paracetamol-induced liver injury) from control (paracetamol overdose without any injury). Final milestone will deliver a Test can distinguish healthy from diseased
Collaborator Contribution Partners are contributing system and domain expertise
Impact early in CiC
Start Year 2013
 
Description CiC fetaSAFE 
Organisation Perkin Elmer
Country United States 
Sector Private 
PI Contribution We have developed a system for the sample concentration and purification of fetal DNA from maternal blood
Collaborator Contribution Perkin Elmer hare developing tests in this arena and are interested in techniques that can increase the opportunity for low fetal DNA samples to be suitable for assay
Impact materials are being provided by partner for evaluation in the device to bench mark to current technology
Start Year 2015
 
Description CiC fetaSAFE 
Organisation Sequenom
Country United States 
Sector Private 
PI Contribution The fetaSAFE team have developed a sample processing device for improving the success rate and potentially lowering the cost barriers to analysis of fetal DNA in maternal circulation.
Collaborator Contribution Sequenom are the world leaders in fetal DNA testing and are engaged in advising and providing bench marking samples for evaluation in the microfluidics technology.
Impact test data not available yet
Start Year 2016
 
Description CiC1 - Micro-BRT 
Organisation Mercia Technologies PLC
PI Contribution Applied and presented the opportunity to the company
Collaborator Contribution Applied and presented the opportunity to the company
Impact Mercia has noted an expression of interest to fund this project, which is building a company proposition around Point of Care monitoring for anti-microbial therapy. Potential £50k for Pathfinder award.
Start Year 2018
 
Description Industry partners, Waters, sponsored Androgens conference 2018 (mass spec) 
Organisation Waters Corporation
Department Waters Corporation Centre of Mass Spectrometry Excellence
Country United Kingdom 
Sector Private 
PI Contribution We collaborated with Waters Corp on a CASE studentship application which unfortunately was unsuccessful. We are reapplying in 2019.
Collaborator Contribution Waters Corp agreed to be on of the main sponsors for the Androgens 2018 conference held in Edinburgh which had an international reach.
Impact This conference took place in Edinburgh on 3rd to 5th September 2018, and featured an update on cutting-edge science and provided an excellent opportunity for the research community to foster further collaboration. Plenary lectures by leading experts covered a wide range of exciting research. T
Start Year 2018
 
Description MicroBRT CiC 
Organisation Axis-Shield
Country United Kingdom 
Sector Private 
PI Contribution The MicroBRT project seeks to identify the micro RNA signature from treatment of bacterial pathogens by antibiotics and organise the purification of the analyte using a microfluidic system.
Collaborator Contribution Designing and developing the microfluidic sample processing system.
Impact The partners provided considerable input to the Target Product Profile and the final milestone of the CiC. Discussions are on going regarding next stage of development. A student ship has been initiated on the background science.
Start Year 2016
 
Description Multiplicom collaboration (Fetasafe) 
Organisation Multiplicom N.V.
Country Belgium 
Sector Private 
PI Contribution PhD role
Collaborator Contribution Multiplicom provided £10k cash to support the PhD role.
Impact PhD completion
Start Year 2013
 
Description Platts and Nisbet - Hepatic Vascular Catheter CIC1 
Organisation Platts & Nisbett Ltd
PI Contribution Provide medical device specifications for prototype and final version - the Currie Clamp
Collaborator Contribution Expertise to made the medical device prototype - the Currie Clamp
Impact Medical device is being used in the Royal Infirmary of Edinburgh. This device prolongs the life of the liver during transplantation. Design protection is being discussed to enable the device for general use in surgical community.
Start Year 2016
 
Title Tissue Manipulation Device 
Description Histology device to reduce cross contamination The present invention relates to methods and devices for use in tissue manipulation, particularly to devices for use in preparation of tissue samples for histological or pathological analysis. Embodiments of the invention relate to devices which are adapted to manipulate tissue samples without coming into physical contact with the tissue samples, thereby avoiding issues of cross-contamination. This can be achieved by coating the tip of the devices with a tissue medium which is used to indirectly manipulate the tissue sample, and then release the sample by melting the tissue medium. 
IP Reference WO2015015228 
Protection Patent application published
Year Protection Granted
Licensed No
Impact Initiated significant discussions with leading companies
 
Title UV-Vis fluorescence diagnostics of cataract 
Description an instrument using a 315nm-LED and interference filter provides a safe light for detection of cataracts based on modification of the non tryptophan 430nm band generating an optical excitation 310-320nm range. This will provide early detection of cataracts and a quantitative measure of change by deterioration or therapy. 
IP Reference GB1323130.3 
Protection Patent application published
Year Protection Granted
Licensed No
Impact The EUR2.7M grant
 
Title microRNA biomarkers of drug-induced liver injury 
Description microRNA biomarkers of drug-induced liver injury 
IP Reference GB1512219.5 
Protection Patent application published
Year Protection Granted
Licensed Yes
Impact supporting development
 
Title CiC EPDD 001 Fibre optic surgical device enabling targeted drug delivery to the posterior eye 
Description The product is designed to provide a device that can direct a laser system for reducing the thickness of the sclera at the back of the eye sufficiently for drugs to permeate into the back of the eye. Final milestone ex-vivo demonstration of viable surgical scheme and proof of concept in terms of enhanced drug transport through sclera. The prototype device can deliver a 1-2mm2 array of portals of 100-200um depth that allows increased penetration of large molecule agents. 
Type Therapeutic Intervention - Surgery
Current Stage Of Development Initial development
Year Development Stage Completed 2014
Development Status Under active development/distribution
Impact We are actively seeking further funding and company spinout options. 
 
Title CiC EPDD 002 CATANOSTICS 
Description An Instrument for the Early Diagnosis of Cataracts. The product is designed to replace the slit detector with an monitoring of Trytophan Fluorescence using LED for both diagnosis and as a research tool enabling the assessment in trials of pharmaceutical interventions (e.g. N- Acetyl Carnosine as published) as well as the femtosecond laser potential therapy pathway. Final milestone involves building a research prototype machine. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact too early in project. Supporting grant application. 
 
Title CiC EPDD 003 Developing Mass Spectrometric Imaging of Estrogens in Hormone Sensitive Tumours of the Breast. 
Description The product will be a compound suitable for facilitating the analytical detection of estrogens in tissue samples. Final milestone will demonstrate FTICR-MS can detect reproducibly androgens and estrogens in breast tumour tissue with RSD<20% and a signal to noise for quantitation >3 and the result can be reported as a quantitative outcome suitable for diagnosis and clinical trials. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact too early in CiC 
 
Title CiC EPDD 004 fetaSAFE - Microfluidic concentration of circulating foetal nucleic acids from maternal blood. 
Description The product will be a sample preparation micro fluidic device that will allow rapid separation and concentration of foetal DNA suitable for non-invasive prenatal diagnosis of foetal disease and treatment needs such as for rhesus factor incompatibility. Final milestone will demonstrate if enough cffDNA can be concentrated from maternal blood to make this process useful for NIPD in the first trimester of pregnancy. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Initial development
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact Too early in CiC. worth noting that following an oral presentation considerable interest has been generated and discussions with two key companies have been initiated. 
 
Title CiC EPDD 005 Delivering personalised voices for patients with MND. 
Description The product will be system suitable for professional speech therapist to build a personalised voice using any residual patient voice and sampling the voice bank. Final milestones all achieved the voice banking tools consists of - SpeechRecorder (iPhone/iPad) - Easy-to-use speech recording apps using specially designed texts. - Voice Cloning Toolkit (Mac) - Mac software for building speech synthesizers from recorded audio files - SpeakUnique (iPhone/iPad) - Communication apps for patients who want to use their own voices - SAPI5 (Windows) - Text-to-speech engine that can use patient's voices on Windows-based AAC devices such as Tobii or DynaVox. All the above tools have been evaluated and validated by clinicians, speech therapists, and patients and have been iteratively refined many times. As planned, our clinicians and speech therapists have successfully recorded, built and delivered two patient's voices without asking IT researchers or teams. The first patient's voice have been delivered using iPad mini. The second patient's voice have been delivered using SAPI5. 
Type Management of Diseases and Conditions
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2013
Development Status Under active development/distribution
Clinical Trial? Yes
Impact We are currently evaluating the potential to establish a company to control the process of manufacture distribution and license. 
 
Title CiC EPDD 006 A Device for Label-Free Purification of Viable Cells for Therapy. 
Description The product will be the operative component in a device that separates cells prior to their administration to patients (or other uses) to eliminate dead cells with inhibitory, toxic and proinflammatory properties. Final milestone will deliver a design with potential to be CE marked, manufactured to GMP and works when sterilized that can robustly remove dead cells with the same levels of proficiency (minimally 90% as proficient) as the prototype with at least two cell types with retention of sterility throughout sorting process. 
Type Support Tool - For Medical Intervention
Current Stage Of Development Initial development
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact Early in CiC 
 
Title CiC EPDD 007 Microsystems for the monitoring of Bacterial Response to Therapy. 
Description The product will deliver isolation and lysis of bacteria in a microfluidic system with the same response pattern as conventional micro RNA analysis reporting on suitability on antibiotic therapy choice for incorporation into an established analyser. Final milestone will deliver a comprehensive head to head comparison of known biomarkers of bacterial response, coordinated with potential commercial partner. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Initial development
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact early in CiC 
 
Title CiC EPDD 008 Tissuestik 
Description The product already at initial prototype, is a non-contact device for handling histopathology samples that reduces the risk of sample cross-contamination and patient misdiagnosis. Final milestone will deliver data comparing macro, micro and molecular contamination against the current gold standard suitable for publication. It has been demonstrated in a blinded trial to remove cross contamination that occurs within 10 manipulations with current optimal process. 
Type Support Tool - For Medical Intervention
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact The development of this product has help a company to be formed TissuePlex Ltd that is developing a range of improved devices for histology. The team have obtained a TSB grant to develop a water bath product. These innovations will improve processing for current histology and significantly remove the opportunity for error with the evolving field of molecular histology. 
 
Title CiC EPDD 009 Development of a hepatic vascular catheter to improve outcomes during liver transplantation. 
Description The product will assist difficult transplants (when cirrhosis is present) when separating the liver form the cava is even more taxing and dangerous and may add several hours to an operation which already takes between 6-10 hours. Reducing the risk of catastrophic bleeding and need for upwards of 40 units of blood, additional clotting factors and a prolonged stay in intensive care would be expected for those patients who survive (£1000 per day in ITU). Final milestone will deliver a device fully evaluated in a large animal model. The first prototype has been evaluated ex vivo and in vivo evaluations are due to take place as soon as the license is secured and the surgical training is complete. 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Initial development
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact The Investigator has received an award from the CSO to provide one day per week to focus on innovation. His next product idea won the local innovation competition and was kick-started with the £15,000 prize. 
 
Title CiC EPDD 010 A portable integrated device for organ recovery from donors after circulatory death under normothermic conditions. 
Description The product is a portable oxygenation system that would support with a portable extracorporeal membrane oxygenation ECMO for organ recovery from donors after circulatory death is performed. Fewer organs are recovered compared to brain-dead donors (1.7 vs 3.2 organs/donor) and transplantation is associated with more complications. Final milestone will deliver a product will be tested in a head to head comparison with the current equipment used in clinicalractice and will be equivalent capabilities but portable. 
Type Support Tool - For Medical Intervention
Current Stage Of Development Initial development
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact early in CiC 
 
Title CiC EPDD 011 mirPOC - detection of miRNAs indicating drug-induced liver injury at point-of-care. 
Description The final product will be an EIS-based assay that has potential to integrate with the Mölnlycke Health Care-Scotland (MHC-S) handset within 1 hour within 10% of PCR fold change. Results clearly distinguish disease (paracetamol-induced liver injury) from control (paracetamol overdose without any injury). Final milestone will deliver a Test can distinguish healthy from diseased by measuring miR-122 levels in 500 clinical samples. Difference in signal >10 fold. Lower limit of the 95% CI >3 fold. Initial deliverables of limit of detection and specificity have been achieved 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Initial development
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact Establishing a strong working relationship with local company Mölnlycke Health Care-Scotland 
 
Title Currie Clamp - Hepatic Vascular Cathetar CIC1 
Description The 'Currie Clamp' was developed as the original CiC device, hepatic vascular catheter, was more complex to handle in use than expected and technical concerns would prevent direct use in humans. The final version of the Currie Clamp was made by a company in Sheffield, Platts and NISBET, from Sheffield Steel. It is CE marked and is in use in the Royal Infirmary. Discussions have started on design protection so it can be made available to the surgical community. 
Type Support Tool - For Medical Intervention
Current Stage Of Development Small-scale adoption
Year Development Stage Completed 2017
Development Status Under active development/distribution
Impact The Currie Clamp lengthens the life of the liver during transplantation. 
 
Description Clinical Pilot Study - CiC1 MND 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Study participants or study members
Results and Impact Funding from Scottish Government in April 2016 for 12 months £200k, set up a clinical pilot to test the application of our voicebanking technology offered within the NHS. Under this exciting development, speech and language therapists have been trained to use the voicebanking technology and the pilot will assess its application as part of routine clinical care. Initially the pilot is being rolled out in the Lothian, Forth Valley and Greater Glasgow and Clyde health boards, with rural areas covered under the remit of the Scottish Centre of Technology for the Communication Impaired (SCTCI). People with communication impairments who are eligible will be invited to take part by their local speech and language therapists. The pilot will include the collection of both qualitative and quantitative data.
Year(s) Of Engagement Activity 2016